32 results
Thumbnail

D2.422 - Supporting second victims: linkages between patient safety and well-being of healthcare workers in allergy departments

Thumbnail

D2.423 - Occupational sensitisation to Chrysonilia sitophila in an asthmatic patient with nasal polyposis

Thumbnail

D2.424 - Allergenic and inflammatory response of combined exposure of shrimp tropomyosin and microbial components in vitro

Thumbnail

D2.425 - Prevalence of Latex Sensitization Among Nursing Staff in Intensive Care Units at the Hospital Universitario Austral: Comparative Analysis and Associated Factors

Thumbnail

D2.426 - Occupational Asthma Due to Tenebrio Molitor in the Owner of a Mealworm Farm: A Case Report

Thumbnail

D2.428 - Asthma severity and work exposure in 66 patient reffered to occupational and allergy unit

Thumbnail

D2.429 - Biologic Therapy in Occupational Asthma: A Multicenter Retrospective Study on Treatment Outcomes and Occupational Impact

Thumbnail

- D3.100 - Risk Factors and Biomarkers for COVID-19 and Allergic Diseases

Thumbnail

- D3.102 - PROMs Improvement Effects of Biologics in Chronic Rhinosinusitis with Nasal Polyps Patients: Real-life Experience

Thumbnail

- D3.103 - Impact of aspirin-induced bronchospasm on the in vitro Aspirin Hypersensitivity Diagnostic Index in the patients with Aspirin Exacerbated Respiratory Disease

Thumbnail

- D3.104 - A step towards standardized Clinical Remission Criteria for Chronic Rhinosinusitis with Nasal Polyps (CRSwNP): insights from a real-life study

Thumbnail

- D3.105 - Suspected EGPA in a patient on Dupilumab treatment: confirmed diagnosis of sarcoidosis - case report

Thumbnail

- D3.106 - Real-World Dupilumab Effectiveness Through 18 Months in Patients with CRSwNP and Coexisting Asthma: Results from the Global AROMA Registry

Thumbnail

- D3.108 - PTGDR2 Blood Expression as a Potential Biomarker for Predicting Super-Response to IL-5-Targeted Therapies in Severe Asthma

Thumbnail

D3.109 - Lichen planus following dupilumab treatment in patients with severe asthma and nasal sinus polyposis

Thumbnail

- D3.110 - Contribution of biotherapies in the reintroduction of NSAIDs in patients with moderate to severe asthma, hypersensitive to COX-1 inhibitor NSAIDs

Thumbnail

- D3.111 - Lymphocyte profile and asthma control during the treatment with benralizumab in real life

Thumbnail

- D3.112 - Role of nasal cytology in patients with bronchial asthma

Thumbnail

- D3.113 - In silico system pharmacology modeling provides insights into a mechanism for greater potency of TSLP/TSLPR pathway inhibition with verekitug, a novel antibody antagonist of TSLPR, as compared to tezepelumab

Thumbnail

- D3.99 - Early Real-World Outcomes of Tezepelumab in Severe Asthma Patients Unresponsive to Prior Biologics